Compare Goldman Sachs Group Inc (GS) vs Kymera Therapeutics Inc. Common Stock (KYMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goldman Sachs Group Inc vs Kymera Therapeutics Inc. Common Stock — how do they compare? Goldman Sachs Group Inc trades at $859.78 (market cap $255.86B), while Kymera Therapeutics Inc. Common Stock trades at $107.09 (market cap $8.88B). The key difference: Goldman Sachs Group Inc is far larger — about 28.8× Kymera Therapeutics Inc. Common Stock's market cap, and Goldman Sachs Group Inc pays a 2.28% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Goldman Sachs Group Inc for 100 Days and Kymera Therapeutics Inc. Common Stock for 0 Days on average.
| GS | KYMR | |
|---|---|---|
Market Cap | $255.86B | $8.88B |
Volume | 3,405,238 | 1,028,790 |
Sector | Financials | Health |
52-Week High | $1.15K | $127.31 |
52-Week Low | $744.60 | $55.80 |
Typical Hold Time | 100 Days | 0 Days |
Enterprise Value | $255.77B | $8.27B |
Dividend Yield | 2.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Goldman Sachs (GS) trades at $891.91, down 0.23% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q3 2026) and improving profitability (net margin 31.68%, ROE 18.33%). Revenue growth accelerated to $58.28B in 2025 with guidance targeting $70B. Recent news highlights AI expansion and wealth management growth, though Q3 FICC business may soften.
GS presents a compelling value opportunity with attractive valuation (P/E 13.77) and 40% analyst buy ratings. Upside to $1,160 consensus target offers ~30% potential, supported by dividend growth and operational efficiency. Risks include market volatility, competitive pressures, and execution on AI/wealth management expansion. The balance sheet remains robust with $122B equity despite negative operating cash flows.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →
